Growth differentiation factor 15 (GDF-15) is a relatively new
biomarker that predicts adverse
stroke outcomes. However, the association of
GDF-15 with first-ever
stroke in hypertensive patients has not yet been evaluated. The objective of this study was to evaluate the clinical implications of plasma
GDF-15 on the development of first-ever
stroke in patients with
hypertension.In total, 254 patients with
hypertension without a history of
stroke were included from March 2010 to August 2010 and followed up until June 2013. The baseline circulating
GDF-15 was determined by
enzyme-linked
immunosorbent assays.During a follow-up of 3.0 ± 0.6 years, 22 (8.7%) first-ever
strokes were identified, including 12
ischemic strokes and 10
intracerebral hemorrhages (ICH). According to tertiles of
GDF-15, survival free of first-ever
stroke was lower in the highest tertile of
GDF-15 (log-rank P = 0.001). By backward stepwise Cox-regression analysis, adjusted for age, gender,
diabetes mellitus,
hyperlipidemia,
hypertension stage, body mass index, cigarette smoking,
anti-hypertensive drugs, and
uric acid, every 100 pg/mL-increase in plasma of
GDF-15 predicted an 11% greater risk of first-ever
stroke (hazard ratios [HR]: 1.11, 95% confidence interval [CI]: 1.03-1.20, P = 0.010) and an 18% increase in
ischemic stroke risk (HR: 1.18, 95% CI: 1.07-1.30, P = 0.001). Receiver operating characteristic analysis indicated that
GDF-15 had reasonable accuracy to predict first-ever
stroke (area under curve = 0.73, 95% CI: 0.62-0.83, P < 0.001).This study identifies that
GDF-15 is an independent predictor of first-ever
stroke, especially for
ischemic stroke in the patients with
hypertension.